This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Head and Neck Cancer > Head and Neck Cancer > Squamous Cell Carcinoma



October 2021

Tislelizumab for oesophageal cancer – second line

Tislelizumab is being developed for patients with recurrent locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic therapy. Advanced or metastatic ESCC begins in the food pipe and spreads to other parts of the body. Symptoms include difficulty swallowing, persistent indigestion or heartburn, weight loss, pain in the throat, and chronic cough. …

Get Alerts